CASP9 and prostate carcinoma: Similarly, pretreatment with caspase-9 and caspase-3 inhibitors (Figure 6B) or the ER stress inhibitor Salubrinal (Figure 6C) significantly inhibited the Shikonin induced caspase activation in DU-145 and PC-3 prostate cancer cells.